RegulatoryOfficial
MHRA to legislate on revised gene therapy definition after strong consultation support
🇬🇧 MHRA · Thu 19 Nov 2026
The MHRA and Northern Ireland's health department will pursue secondary legislation to update how gene therapy medicinal products are defined, after 83% of 48 respondents backed the proposals.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its response to a consultation on updating the definition of gene therapy medicinal products (GTMPs) in the Human Medicines Regulations 2012. The response appeared on 19 November 2026. The agency ran the six-week exercise jointly with Northern Ireland's Department of Health.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.
More Regulatory
All →
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026
UK confirms plan to widen gene therapy definition to cover synthetic and genome-editing products
🇬🇧 MHRA · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 190/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends veterinary, phytosanitary and technical regulation annexes in Decision No 194/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 191/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026